The role of GRACE score in the prediction of high-risk coronary anatomy in patients with non-ST elevation acute coronary syndrome

2015 ◽  
pp. 592-597 ◽  
Author(s):  
Burcak Kilickiran Avci ◽  
Baris Ikitimur ◽  
Ozge Ozden Tok ◽  
Murat Cimci ◽  
Emre Erturk ◽  
...  
2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Sida Jia ◽  
Ce Zhang ◽  
Yue Liu ◽  
Deshan Yuan ◽  
Xueyan Zhao ◽  
...  

Objective. We aim to evaluate the long-term prognosis of non-ST elevation acute coronary syndrome (NSTE-ACS) patients with high-risk coronary anatomy (HRCA). Background. Coronary disease severity is important for therapeutic decision-making and prognostication among patients presenting with NSTE-ACS. However, long-term outcome in patients undergoing percutaneous coronary intervention (PCI) with HRCA is still unknown. Method. NSTE-ACS patients undergoing PCI in Fuwai Hospital in 2013 were prospectively enrolled and subsequently divided into HRCA and low-risk coronary anatomy (LRCA) groups according to whether angiography complies with the HRCA definition. HRCA was defined as left main disease >50%, proximal LAD lesion >70%, or 2- to 3- vessel disease involving the LAD. Prognosis impact on 2-year and 5-year major adverse cardiovascular and cerebrovascular events (MACCE) is analyzed. Results. Out of 4,984 enrolled patients with NSTE-ACS, 3,752 patients belonged to the HRCA group, while 1,232 patients belonged to the LRCA group. Compared with the LRCA group, patients in the HRCA group had worse baseline characteristics including higher age, more comorbidities, and worse angiographic findings. Patients in the HRCA group had higher incidence of unplanned revascularization (2 years: 9.7% vs. 5.1%, p<0.001; 5 years: 15.4% vs. 10.3%, p<0.001), 2-year MACCE (13.1% vs. 8.8%, p<0.001), and 5-year death/MI/revascularization/stroke (23.0% vs. 18.4%, p=0.001). Kaplan–Meier survival analysis showed similar results. After adjusting for confounding factors, HRCA is independently associated with higher risk of revascularization (2 years: HR = 1.636, 95% CI: 1.225–2.186; 5 years: HR = 1.460, 95% CI: 1.186–1.798), 2-year MACCE (HR = 1.275, 95% CI = 1.019–1.596) and 5-year death/MI/revascularization/stroke (HR = 1.183, 95% CI: 1.010–1.385). Conclusion. In our large cohort of Chinese patients, HRCA is an independent risk factor for long-term unplanned revascularization and MACCE.


2016 ◽  
Vol 117 ◽  
pp. S9
Author(s):  
Mustafa Öztürk ◽  
Lütfü Aşkın ◽  
Selami Demirelli ◽  
Oğuzhan Ekrem Turan ◽  
Emrah İpek ◽  
...  

Author(s):  
Elizabete Silva dos Santos ◽  
Luciano de Figueiredo Aguiar Filho ◽  
Daniela Menezes Fonseca ◽  
Hugo José Londero ◽  
Rogério Martins Xavier ◽  
...  

Doctor Ru ◽  
2019 ◽  
Vol 157 (2) ◽  
pp. 12-18
Author(s):  
S.A. Berns ◽  
◽  
E.A. Shmidt ◽  
A.V. Klimenkova ◽  
S.A. Tumanova ◽  
...  

2014 ◽  
Vol 55 (3) ◽  
pp. 219-227 ◽  
Author(s):  
Guoxin Tong ◽  
Ningfu Wang ◽  
Yujie Zhou ◽  
Jianhang Leng ◽  
Wei Gao ◽  
...  

Heart ◽  
2021 ◽  
pp. heartjnl-2020-318778
Author(s):  
Thomas A Kite ◽  
Andrew Ladwiniec ◽  
J Ranjit Arnold ◽  
Gerry P McCann ◽  
Alastair J Moss

Non-ST-elevation acute coronary syndrome (NSTE-ACS) comprises a broad spectrum of disease ranging from unstable angina to myocardial infarction. International guidelines recommend a routine invasive strategy for managing patients with NSTE-ACS at high to very high-risk, supported by evidence of improved composite ischaemic outcomes as compared with a selective invasive strategy. However, accurate diagnosis of NSTE-ACS in the acute setting is challenging due to the spectrum of non-coronary disease that can manifest with similar symptoms. Heterogeneous clinical presentations and limited uptake of risk prediction tools can confound physician decision-making regarding the use and timing of invasive coronary angiography (ICA). Large proportions of patients with suspected NSTE-ACS do not require revascularisation but may unnecessarily undergo ICA with its attendant risks and associated costs. Advances in coronary CT angiography and cardiac MRI have prompted evaluation of whether non-invasive strategies may improve patient selection, or whether tailored approaches are better suited to specific subgroups. Future directions include (1) better understanding of risk stratification as a guide to investigation and therapy in suspected NSTE-ACS, (2) randomised clinical trials of non-invasive imaging versus standard of care approaches prior to ICA and (3) defining the optimal timing of very early ICA in high-risk NSTE-ACS.


Sign in / Sign up

Export Citation Format

Share Document